Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
Enter Symbol
Company
Overview
Research Notes
Company Profile
Competitors
Community
Wiki
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Related News
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
480M
Market Cap:
$0.74B
Avg Volume:
562515
P/E Ratio:
-0.010
PEG Ratio:
-0.010
Trade now with
1m
3m
6m
1y
2y
Opinion and Analysis
Two Stocks Set To Benefit As Healthcare Goes Digital
Jan 14, 2011 05:23 PM |
GOOG
,
HOTT
,
IMGN
,
JPM
,
LXRX
,
MCK
Stocks Indicated Higher At Open - Jobless Claims Rise Trims Stronger Early Futures Gain
Jan 06, 2011 09:19 AM |
ARMH
,
COST
,
JCP
,
LTD
,
LXRX
,
MSFT
The Next Wave Of Blockbuster Diabetes Drugs
Sep 10, 2010 02:36 PM |
AZN
,
BBI
,
BMY
,
JNJ
,
LXRX
How Will Obama-Care Play Into The Markets And ETFs?
Mar 22, 2010 01:27 AM |
ABT
,
ACOR
,
ADLR
,
AET
,
AFFX
,
AGN
Lexicon Pharmaceuticals, Inc. Successfully Completes Phase 1b Trials for LX1032
Nov 14, 2008 04:14 PM |
LXRX
More Articles on LXRX..
Market News
More News on LXRX..
Press Releases
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
May 03, 2012 07:00 AM |
LXRX
Lexicon to Provide First Quarter 2012 Financial Results
Apr 25, 2012 06:00 PM |
LXRX
Lexicon Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Mar 27, 2012 06:00 PM |
LXRX
More Press Releases on LXRX..
SEC Filings
Form 4/A LEXICON PHARMACEUTICALS, For: Apr 27 Filed by: DEBBANE RAYMOND (10K)
May 01, 2012 04:37 PM
Form 4 LEXICON PHARMACEUTICALS, For: Apr 27 Filed by: Palantoni Frank (10K)
Apr 27, 2012 04:51 PM
Form 4 LEXICON PHARMACEUTICALS, For: Apr 27 Filed by: Swain Judith L (10K)
Apr 27, 2012 04:51 PM
More SEC Filings on LXRX..
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
LXRX
Compare to S&P
YTD
18.60 %
9.66 %
4 Weeks
-9.47 %
-8.63 %
12 Weeks
-12.57 %
-13.71 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
33.33 %
EPS Growth in Last Year:
25.00 %
Sales Growth in Last Quarter:
-12.54 %
Sales Growth in Last Quarter:
-49.66 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##